Latest Options News

Sprintex Limited reported a 162% surge in revenue to A$2.7 million for the half-year ending December 2025, driven by a landmark €15.6 million European contract. Despite this, the company posted a net loss of A$1.7 million, an improvement from the prior year, while raising $3.6 million to support global expansion.

Suncorp Group Limited has updated its dividend distribution details, confirming a fully franked ordinary dividend of AUD 0.17 per share payable in March 2026, with tailored currency payment options for shareholders.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Acorn Capital Investment Fund Limited has reported a remarkable half-year performance for the period ending 31 December 2025, with revenue and profit soaring over 300%. The fund also declared a fully franked interim dividend of 3.5 cents per share, signalling confidence in its investment strategy.

MA Credit Income Trust reported a strong half-year profit of $19.7 million, exceeding its return target, while successfully completing a $190.5 million capital raise and initiating a strategic buy-back to manage liquidity.

Ironbark Balanced Income Limited reported a solid half-year profit increase of 14.6%, driven by strong portfolio returns and a strategic shift to quarterly dividends. The company declared a fully franked interim dividend of 1.3 cents per share payable in March 2026.

Pharmx Technologies reported a 3.1% revenue increase to $3.89 million for H1 FY26 but posted a net loss of $512,000 driven by strategic investments. The company also announced a significant multi-year alliance with Sigma Healthcare.

Kali Metals has acquired SQM Australia’s 30% stake in the DOM’s Hill and Pear Creek projects, consolidating its Pilbara portfolio and setting the stage for renewed gold and base metals exploration.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Meridian Energy has reported a robust turnaround with a NZD 227 million net profit after tax for the first half of 2026, driven by record wind generation and strong hydro inflows. The company also raised its interim dividend and advanced multiple renewable projects.